First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma

  • First patient dosed with QBiotics' lead oncology molecule tigilanol tiglate in combination with KEYTRUDA® (pembrolizumab) in a clinical trial collaboration with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA)
  • The Phase Ib/IIa study will test the safety, optimal dose and tumour response of the combination in patients with...

Read more: First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma

More Articles …

  1. Cell Care Joins the Generate Life Sciences Family to Create a Global Platform
  2. Fisher Investments Launches Private Client Group in Australia
  3. Nintex Acquires eSignature Leader AssureSign
  4. Award-winning payment provider of the year launches their IDO
  5. Locus raises $50 million in Series C funding led by GIC with participation from Qualcomm Ventures and existing investors
  6. Hublot And Chelsea FC Top The UEFA Champions League
  7. Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site
  8. Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials
  9. Australia's original prolonged-release melatonin now available over the counter at pharmacies
  10. With 681 Million 5G Handsets Set to Ship in 2022, Mobile Device Vendors Scramble for Differentiation